T1	Participants 422 464	AH-resistant and AH responder CIU patients
T2	Participants 880 932	sex- and age-matched patents with allergic rhinitis.
T3	Participants 146 194	patients with chronic idiopathic urticaria (CIU)
T4	Participants 466 535	CIU patients with treatment failure under fexofenadine at 180 mg q.d.
T5	Participants 589 680	Those with significant improvement of urticaria activity score under fexofenadine at 180 mg
T6	Participants 713 798	Subjects with treatment failure despite a full 8-week fourfold fexofenadine treatment
